A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17)
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-7217
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17) ; volume:190 ; number:3 ; day:23 ; month:9 ; year:2021 ; pages:425-434 ; date:12.2021
Breast cancer research and treatment ; 190, Heft 3 (23.9.2021), 425-434, 12.2021
- Creator
-
Fukada, Ippei
Ito, Yoshinori
Kondo, Naoto
Ohtani, Shoichiro
Hattori, Masaya
Tokunaga, Eriko
Matsunami, Nobuki
Mashino, Kohjiro
Kosaka, Taijiro
Tanabe, Masahiko
Yotsumoto, Daisuke
Yamanouchi, Kosho
Sawaki, Masataka
Kashiwaba, Masahiro
Kawabata, Hidetaka
Kuroi, Katsumasa
Morita, Satoshi
Ohno, Shinji
Toi, Masakazu
Masuda, Norikazu
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10549-021-06396-0
- URN
-
urn:nbn:de:101:1-2022010918452761436639
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:29 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Fukada, Ippei
- Ito, Yoshinori
- Kondo, Naoto
- Ohtani, Shoichiro
- Hattori, Masaya
- Tokunaga, Eriko
- Matsunami, Nobuki
- Mashino, Kohjiro
- Kosaka, Taijiro
- Tanabe, Masahiko
- Yotsumoto, Daisuke
- Yamanouchi, Kosho
- Sawaki, Masataka
- Kashiwaba, Masahiro
- Kawabata, Hidetaka
- Kuroi, Katsumasa
- Morita, Satoshi
- Ohno, Shinji
- Toi, Masakazu
- Masuda, Norikazu
- SpringerLink (Online service)
Other Objects (12)
Real-world data of HER2-negative early breast cancer patients treated with anthracycline and/or taxane regimens in Japan
Combination chemotherapy with mitomycin C and methotrexate is active against metastatic HER2-negative breast cancer even after treatment with anthracycline, taxane, capecitabine, and vinorelbine
Evaluating anthracycline + taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study
Carbonic anhydrase 9 is associated with chemosensitivity and prognosis in breast cancer patients treated with taxane and anthracycline
Impact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studies
Sequential vs concurrent adjuvant chemotherapy of anthracycline and taxane for operable breast cancer
Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance
Taxane combined with lobaplatin or anthracycline for neoadjuvant chemotherapy of triple-negative breast cancer: a randomized, controlled, phase II study
Eribulin plus carboplatin combination for HER2-negative metastatic breast cancer: a multicenter, real-world cohort study
Weekly taxane–anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial
Prognostic and predictive value of TP53mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial
Pegylated liposomal doxorubicin (Duomeisu®) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study
Real-world data of HER2-negative early breast cancer patients treated with anthracycline and/or taxane regimens in Japan
Combination chemotherapy with mitomycin C and methotrexate is active against metastatic HER2-negative breast cancer even after treatment with anthracycline, taxane, capecitabine, and vinorelbine
Evaluating anthracycline + taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study
Carbonic anhydrase 9 is associated with chemosensitivity and prognosis in breast cancer patients treated with taxane and anthracycline
Impact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studies
Sequential vs concurrent adjuvant chemotherapy of anthracycline and taxane for operable breast cancer
Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance
Taxane combined with lobaplatin or anthracycline for neoadjuvant chemotherapy of triple-negative breast cancer: a randomized, controlled, phase II study
Eribulin plus carboplatin combination for HER2-negative metastatic breast cancer: a multicenter, real-world cohort study
Weekly taxane–anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial
Prognostic and predictive value of TP53mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial
Pegylated liposomal doxorubicin (Duomeisu®) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study
Real-world data of HER2-negative early breast cancer patients treated with anthracycline and/or taxane regimens in Japan
Combination chemotherapy with mitomycin C and methotrexate is active against metastatic HER2-negative breast cancer even after treatment with anthracycline, taxane, capecitabine, and vinorelbine
Evaluating anthracycline + taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study
Carbonic anhydrase 9 is associated with chemosensitivity and prognosis in breast cancer patients treated with taxane and anthracycline
Impact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studies
Sequential vs concurrent adjuvant chemotherapy of anthracycline and taxane for operable breast cancer
Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance
Taxane combined with lobaplatin or anthracycline for neoadjuvant chemotherapy of triple-negative breast cancer: a randomized, controlled, phase II study
Eribulin plus carboplatin combination for HER2-negative metastatic breast cancer: a multicenter, real-world cohort study
Weekly taxane–anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial
Prognostic and predictive value of TP53mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial